Wu Yu, Xu Manman, Duan Binwei, Li Guangming, Chen Yu
Fourth Department of Liver Disease (Difficult & Complicated Liver Diseases and Artificial Liver Center), Beijing You'an Hospital Affiliated to Capital Medical University, Beijing, China.
Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing, China.
Expert Rev Gastroenterol Hepatol. 2023 Mar;17(3):251-262. doi: 10.1080/17474124.2023.2180630. Epub 2023 Feb 19.
Acute-on-chronic liver failure (ACLF) is a clinical syndrome characterized by intense systemic inflammatory response, multiple-organ failures, and high short-term mortality in patients with chronic liver disease. ACLF is dynamic and heterogeneous, and the prognosis is closely related to the clinical course. Currently, liver transplantation (LT) remains the only potential curative treatment that improves survival of ACLF patients.
In this review, we summarize the dynamic clinical course of ACLF and the relationship between the clinical course and the post-LT prognosis, especially the factors affecting the mortality after LT in severe ACLF patients and explore the optimal choice of LT therapy for ACLF patients, both to benefit patients the most and to avoid futile therapy.
ACLF is a dynamic disease with varying clinical phenotypes, and the global burden is high. Early identification of the clinical course is important to assess the prognosis and guide the treatment. The contradiction between shortage of liver donors and the large number of recipients makes it necessary for us to strictly screen out the recipients and identify patients who really need LT to save liver sources.
慢加急性肝衰竭(ACLF)是一种临床综合征,其特征为慢性肝病患者出现强烈的全身炎症反应、多器官功能衰竭以及高短期死亡率。ACLF具有动态性和异质性,其预后与临床病程密切相关。目前,肝移植(LT)仍然是唯一能够提高ACLF患者生存率的潜在治愈性治疗方法。
在本综述中,我们总结了ACLF的动态临床病程以及临床病程与肝移植后预后之间的关系,特别是影响严重ACLF患者肝移植后死亡率的因素,并探讨ACLF患者肝移植治疗的最佳选择,以使患者受益最大化并避免无效治疗。
ACLF是一种具有不同临床表型的动态疾病,全球负担较重。早期识别临床病程对于评估预后和指导治疗很重要。肝供体短缺与大量受者之间的矛盾使得我们有必要严格筛选受者,识别真正需要肝移植的患者以节省肝脏资源。